Document is current

Article History

Received: 16 December 2022

Accepted: 8 March 2023

First Online: 10 April 2023

Declarations

:

: The SELECT-PsA 1 (NCT03104400) and SELECT-PsA 2 (NCT0310437) studies were conducted in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, applicable regulations governing clinical trial conduct, and the Declaration of Helsinki 1964 and its later amendments. As per Good Clinical Practice (GCP), the trial protocols were approved by an independent ethics committee (IEC)/institutional review board (IRB). A full list of the IECs and IRBs for SELECT-PsA 1 and SELECT-PsA 2 have been published previously []. All patients provided written informed consent.

: Not applicable.

: Financial arrangements of the authors with companies whose products may be related to the present manuscript are listed, as declared by the authors. XB: Received grant/research support from, consultant for, and is a member of speaker bureaus for AbbVie, Bristol Myers Squibb, Celgene, Chugai, Eli Lilly, Galapagos, Gilead, MSD, Novartis, Pfizer, and UCB. RR: Consultant for AbbVie, Janssen, Novartis, and Pfizer; and is a member of speaker bureaus for AbbVie, Janssen, Novartis, and Pfizer. AÖ: Consultant for AbbVie, Bristol Myers Squibb, Eli Lilly, Gilead, MSD, Novartis, Pfizer, and Roche; member of speaker bureaus for AbbVie, Bristol-Myers Squibb, Eli Lilly, Gilead, MSD, Novartis, Pfizer, and Roche. FC: Received grant/research support from AbbVie, Celgene, Pfizer, Roche, and UCB; consultant for AbbVie, Bristol-Myers Squibb, Celgene, MSD, Novartis, Pfizer, Janssen, Sanofi, Sandoz, Galapagos, Sobi, and UCB; member of speaker bureaus for AbbVie, Bristol-Myers Squibb, Celgene, Novartis, Pfizer, and UCB. LCC: Received grant/research support from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB; consultant for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Moonlake, Novartis, Pfizer and UCB; speaker for AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Medac, Novartis, Pfizer and UCB. SR: Received grant/research support from AbbVie, Boehringer Ingelheim, Eli Lilly, MSD, Novartis, Pfizer, and UCB; consultant for AbbVie, Boehringer Ingelheim, Eli Lilly, MSD, Novartis, and Pfizer. JAW: Grants or consulting with AbbVie, Amgen, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB. KD: Employee of AbbVie and may hold stock or options. TG: Employee of AbbVie and may hold stock or options. KK: Employee of AbbVie and may hold stock or options. I-HS: Employee of AbbVie and may hold stock or options. FG: Employee of AbbVie and may hold stock or options. AD: Received research grants, consultancy fees, speaker fees, and other support (medical writing support) from Eli Lilly, Novartis, Pfizer and UCB; research grants, consultancy fees, and other support (medical writing support) from AbbVie, Bristol Myers Squibb, Eli Lilly, and UCB; research grants and consultancy fees from GlaxoSmithKline; consultancy fees and other support (medical writing support) from Janssen; consultancy fees from Bristol Myers Squibb and Celgene; and other support (medical writing support) from Amgen.